摘要
目的:探讨组织病理学同行评议的GLP要求及关注点。方法:简要介绍药物非临床安全性评价领域组织病理学同行评议的指导原则、目的、GLP要求、GLP符合性要求、种类、地点、病理工作组、同行评议病理学家和专题病理学家的职责、动物数量的选择、建议归档文件、同行评议声明以及使用数字扫描全切片图像进行同行评议等内容。结果:组织病理学同行评议可核实并提高病理诊断和病理解释的准确性、一致性及完整性,提高病理报告的质量;同时,可作为毒性病理学家继续教育的重要组成部分。结论:本文探讨组织病理学同行评议的GLP要求及关注点,以期为我国药物非临床安全性评价领域更好地开展符合GLP的组织病理学同行评议提供一些参考。
Objective: To discuss GLP requirements and considerations in peer review of histopathology. Methods: This paper gave a brief introduction to the good laboratory practice (GLP) requirements and considerations in peer review of histopathology in nonclinical safety evaluation of drugs, including guidelines for peer review, purpose of peer review, GLP requirements of peer review, GLP compliant requirements of peer review, types of peer review, site of peer review, pathology working groups (PWGs), responsibilities of peer review pathologists and study pathologists, animal numbers to be reviewed, documents suggested to be archived , peer review statement, as well as utilizing whole slide images (WSIs) for peer review. Results: Peer review of histopathology can verify and improve the accuracy, consistency and completeness of pathology diagnoses and interpretation, improve the quality of the pathology report and serve as an important source of continuingeducation of toxicologic pathologists. Conclusion: ~e GLP requirements and considerations for peer review of histopathology were discussed with the aim to provide some references for better complying with GLP peer review of histopathology in nonclinical safety evaluation of ~gs in China,
作者
吕建军
霍桂桃
林志
屈哲
杨艳伟
张頔
霍艳
耿兴超
王雪
李波
Lv Jianjun;Huo Guitao;Lin Zhi;Qu Zhe;Yang Yanwei;Zhang Di;Huo Yan;Geng Xingchao;Wang Xue;Li Bo(Beijing Key Laboratory for Safety Evaluation of Drugs, National Center for Safety Evaluation of Drugs, National Institutes for Food and Drug Control, Beijing 100176, China;National Institutes for Food and Drug Control, Beijing 100050, China)
出处
《中国药事》
CAS
2018年第4期485-493,共9页
Chinese Pharmaceutical Affairs
基金
十二五国家科技重大专项课题"符合中药特点的有毒中药安评关键技术"(编号2015ZX09501004-002)
十二五国家科技重大专项课题"生物大分子药物特殊评价关键技术研究"(编号2015ZX09501007-004)